Industry

Findings from the Phase 3 study were presented at the 67th American Society of Hematology Annual Meeting and Exposition and published in Blood NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The … [Read more…]

VGA039 is a once monthly, subcutaneously self-administered therapy for the treatment of bleeding disorders, starting with von Willebrand disease (VWD) Multidose data demonstrate substantial reductions in bleeding across all types of VWD and all types of bleeds, including in patients switching from prior von Willebrand factor (VWF)-containing IV prophylaxis Pivotal Phase 3 trial of VGA039 … [Read more…]

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety Signals These Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary Endpoints Patients Crossing Over from Placebo to … [Read more…]

– Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients – – Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in … [Read more…]

Questions Independent Director Mark Greenberg for His Role in Supporting Substantial Dilution of Shareholders and Rebuffing Inbound Interest Intends to Vote Against Every Incumbent Director at 2026 Annual Meeting if the Board Continues to Put Shareholder Value at Risk HOUSTON–(BUSINESS WIRE)–Bradley L. Radoff, who collectively with his affiliates owns approximately 4.9% of the outstanding common … [Read more…]

LYT-200 demonstrated favorable tolerability and strong efficacy in a heavily pretreated population, both in combination with standard of care and as a monotherapy, supporting advancement toward a potentially registrational Phase 2 trial Initial median overall survival of 13.2 months observed in the combination cohort at the proposed Phase 2 dose, exceeding expected late-line relapsed/refractory setting … [Read more…]

NEW YORK–(BUSINESS WIRE)–Arthur D. Little (ADL) and Vega IT today announced the formation of Axceler8 Solutions, a 50/50 joint venture created to design, develop, and operate a portfolio of digital and AI solutions aimed at improving efficiency and automating complex business processes. The launch of this new company is the direct outcome of a year … [Read more…]

Expands Natera’s lead in solid tumor MRD, acquiring ultrasensitive phased variant technology with LOD95 of 0.3 parts per million (ppm) and detection below 0.1 ppm1 Cutting-edge IP adds to Natera’s portfolio of >500 issued or pending patents Accelerates Natera’s expansion into lymphoma, where Foresight has developed a strong clinical position AUSTIN, Texas & BOULDER, Colo.–(BUSINESS … [Read more…]

Sculptra®, the first proven regenerative biostimulator, has received European Union (EU) Medical Device Regulation (MDR) certification, expanding its current clinical application for the face to include gluteal area, posterior thighs, décolletage, and upper arms1 Studies investigating the efficacy of Sculptra on areas beyond the face show patients experienced progressive improvements in skin quality (including the … [Read more…]

In the MZL cohort of TRANSCEND FL, Breyanzi delivered deep and durable responses in 95.5% of patients while demonstrating a consistent safety profile Breyanzi is now the only CAR T cell therapy approved by the FDA for five cancer types, the most of any CD19-directed CAR T cell therapy PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Breyanzi—Bristol Myers Squibb … [Read more…]